Pioglitazone Useful Adjunct to Lipid-Lowering Therapy

Combined hyperlipidemia patients have better myocardial blood flow on combination therapy

THURSDAY, Nov. 15 (HealthDay News) -- Non-diabetic patients with familial combined hyperlipidemia have better myocardial glucose utilization and blood flow when they are treated with pioglitazone in combination with conventional lipid-lowering therapy, according to a report published in the Nov. 20 issue of the Journal of the American College of Cardiology.

Rossi P. Naoumova, M.D., Ph.D., of Imperial College, Hammersmith Hospital in London, U.K., and colleagues conducted a study of 26 patients with familial combined hyperlipidemia who were randomized to receive either placebo or 30 mg/day of pioglitazone for four weeks and a further 45 mg/day for 12 weeks.

Patients in the pioglitazone group had a significant improvement in whole body glucose disposal as well as resting myocardial blood flow. High-density lipoprotein cholesterol and adiponectin levels increased 28 percent and 156.2 percent, respectively, and plasma insulin levels fell 35 percent.

"The results of this pilot study have demonstrated that the addition of pioglitazone to conventional lipid-lowering therapy in familial combined hyperlipidemia patients leads to significant beneficial effects on metabolic and vascular parameters at both whole body and myocardial level beyond those seen with conventional lipid-lowering therapy," the authors write.

Abstract
Full Text (subscription or payment may be required)
Editorial

Physician's Briefing